Investment
Features
FeesSafety
Academy
More
Pluang+

Compare General Motors Company (GM) vs Novo Nordisk A/S (NVO) Price & Performance

General Motors CompanyTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

General Motors Company vs Novo Nordisk A/S — how do they compare? General Motors Company trades at $86.84 (market cap $78.40B), while Novo Nordisk A/S trades at $46.56 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 2.7× General Motors Company's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.

GMNVO
Market Cap
$78.40B$207.85B
Sector
Consumer CyclicalHealth
52-Week High
$90.30$63.98
52-Week Low
$54.16$35.29
Enterprise Value
$181.38B$222.55B
Dividend Yield
0.81%3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

General Motors Company

General Motors (GM) trades at $87.19, down 0.88% on the day, with strong technical momentum showing bullish moving average signals. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.57 exceeding the $3.19 estimate. Recent developments include a $4.5 billion parts supply agreement to mitigate future disruptions and a renewed 20-year joint venture with China's SAIC Motor. Analyst consensus remains strongly positive with a $108.82 price target representing 25% upside potential.

GM presents a compelling investment case with attractive valuation metrics including P/S of 0.45 and EV/EBITDA of 10.35, though profitability metrics remain challenged with net margin at 1.05%. Key risks include declining profit margins from 6.33% in 2022 to 1.45% in 2025, high debt levels with debt-to-asset ratio of 46.79%, and ongoing supply chain challenges in the automotive sector.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.

Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About General Motors Company

General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.

Read more on GM

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO